PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor.
作者信息
Hodoglugil Ugur, Carrillo Michelle W, Hebert Joan M, Karachaliou Niki, Rosell Rafael C, Altman Russ B, Klein Teri E
机构信息
Departments of aGenetics bBioengineering, Stanford University Medical Center, Stanford, California, USA cBreakthrough Cancer Research Unit, Pangaea Biotech, Dexeus University Institute dMedical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain.
出版信息
Pharmacogenet Genomics. 2013 Nov;23(11):636-42. doi: 10.1097/FPC.0b013e3283655091.
Abstract
摘要
相似文献
1
PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor.
Pharmacogenet Genomics. 2013 Nov;23(11):636-42. doi: 10.1097/FPC.0b013e3283655091.
2
The cellular origins of drug resistance in cancer.
Nat Med. 2016 Mar;22(3):232-4. doi: 10.1038/nm.4058.
3
Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Nat Rev Clin Oncol. 2010 Nov;7(11):618-9. doi: 10.1038/nrclinonc.2010.168.
4
Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters.
Pulmonology. 2019 Sep-Oct;25(5):306-309. doi: 10.1016/j.pulmoe.2019.04.005. Epub 2019 Jun 7.
5
Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors.
Clin Lung Cancer. 2004 Dec;6 Suppl 1:S30-4. doi: 10.3816/clc.2004.s.012.
6
Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188363. doi: 10.1016/j.bbcan.2020.188363. Epub 2020 Apr 8.
7
Personalized medicine in lung cancer: what we need to know.
Nat Rev Clin Oncol. 2011 Aug 23;8(11):661-8. doi: 10.1038/nrclinonc.2011.126.
8
[Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer].
Zhongguo Fei Ai Za Zhi. 2017 Jan 20;20(1):61-65. doi: 10.3779/j.issn.1009-3419.2017.01.09.
9
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
J Clin Oncol. 2019 Apr 10;37(11):876-884. doi: 10.1200/JCO.18.00177. Epub 2019 Jan 24.
10
There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
J Clin Pathol. 2017 Sep;70(9):798-802. doi: 10.1136/jclinpath-2017-204370. Epub 2017 Mar 31.
引用本文的文献
1
Ethyl acetate extract of : a specific and potent inhibitor against the drug-resistant EGFR_T790M mutant in NSCLC.
Front Pharmacol. 2025 Apr 29;16:1570108. doi: 10.3389/fphar.2025.1570108. eCollection 2025.
2
Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer.
Front Oncol. 2024 Jul 17;14:1427802. doi: 10.3389/fonc.2024.1427802. eCollection 2024.
3
Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs.
Transl Oncol. 2020 Sep;13(9):100791. doi: 10.1016/j.tranon.2020.100791. Epub 2020 May 31.
4
Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation.
Anal Cell Pathol (Amst). 2018 Oct 14;2018:6192187. doi: 10.1155/2018/6192187. eCollection 2018.
5
Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1.
Pharmacogenomics J. 2018 May 22;18(3):460-466. doi: 10.1038/tpj.2017.40. Epub 2017 Aug 1.
6
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
Pharmacogenomics J. 2017 Jul;17(4):325-330. doi: 10.1038/tpj.2016.31. Epub 2016 Apr 19.
7
The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype.
Mol Cell. 2014 Sep 18;55(6):904-915. doi: 10.1016/j.molcel.2014.08.010. Epub 2014 Sep 11.
8
Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.
Physiol Genomics. 2014 Oct 1;46(19):699-724. doi: 10.1152/physiolgenomics.00062.2014. Epub 2014 Aug 5.
本文引用的文献
1
Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
PLoS One. 2013;8(3):e57528. doi: 10.1371/journal.pone.0057528. Epub 2013 Mar 5.
2
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Cancer Res. 2013 Apr 15;73(8):2428-34. doi: 10.1158/0008-5472.CAN-12-3479. Epub 2013 Feb 4.
3
Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
Cancer Treat Rev. 2013 Aug;39(5):489-97. doi: 10.1016/j.ctrv.2012.09.001. Epub 2012 Sep 28.
4
Pharmacogenomics knowledge for personalized medicine.
Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96.
5
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
J Thorac Oncol. 2012 Oct;7(10):1490-502. doi: 10.1097/JTO.0b013e318265b2b5.
6
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.
Cell. 2012 Sep 14;150(6):1107-20. doi: 10.1016/j.cell.2012.08.029.
7
Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
J Thorac Oncol. 2012 Nov;7(11):1640-4. doi: 10.1097/JTO.0b013e3182653d7f.
8
Genome-wide association study of glioma and meta-analysis.
Hum Genet. 2012 Dec;131(12):1877-88. doi: 10.1007/s00439-012-1212-0. Epub 2012 Aug 11.
9
Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib.
Oncol Lett. 2012 Mar;3(3):713-717. doi: 10.3892/ol.2011.534. Epub 2011 Dec 23.
10
Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.
Pharmacogenomics. 2012 May;13(7):789-802. doi: 10.2217/pgs.12.54.
Zotero 插件